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Introduction: As osteoporosis is reported to be associated with atherosclerosis in the general population we
examined the relationship between bone mass and carotid measurements in patients with systemic lupus
erythematosus (SLE) and controls, and possible links between them in SLE.
Methods: In a cross-sectional study, 111 SLE-patient were compared with 111 age- and sex-matched controls,
mean age 48.7(12.9) years, 89% were women, of which 51% postmenopausal. Carotid intima media thickness (cIMT),
carotid plaque occurrence and echogenicity were determined by B-mode ultrasound and bone mineral density
(BMD) by dual-energy X-ray absorptiometry (DXA).
Results: BMD and cIMT were inversely associated both in patients and controls. Patients, but not controls, with
carotid plaque had higher cIMT at low BMD than at normal BMD, p = 0.010. Logistic regression indicated more than
doubled odds ratio (OR) of carotid plaque in patients, particularly in post-menopausal women, than in controls in
relation to all BMD measurements. For low BMD at hip, significant increased OR for echolucent plaque was shown
for patients compared with controls.
In patients, significant impact of age, body mass index, smoking, systolic blood pressure, blood lipids, diabetes
mellitus, impaired renal function, low levels of complement C3 and C4, history of nephritis, SLE-damage index and
ever use of antimalarial was found for association between BMD and higher cIMT and carotid plaque. In multivariate
regression, low C4 was independent contributor to association between total BMD and upper cIMT tertile,
accounted for OR (95% confidence interval) of 3.2 (1.03-10.01), and also for association with bilateral carotid plaque,
OR of 4.8 (1.03-22.66). The contribution of low C4 for the association between BMD and carotid atherosclerosis was
enhanced within the second and third tertiles of total BMD.
Conclusion: This study is the first to demonstrate inverse association between BMD and carotid measurements in
both SLE-patients and controls. Our results suggest that SLE-patients may suffer higher burden of (sub)clinical
atherosclerotic disease, especially presence of both echolucent and echogenic plaque, than controls with the same
bone mineral status. Low complement C4 seems to play an important role in earlier development of carotid
atherosclerosis already within (sub)normal ranges of total BMD in patients.Introduction
Osteoporosis and osteopenia have been reported to be
associated with atherosclerosis and cardiovascular dis-
ease (CVD) in the general population [1-5]. Both osteo-
porosis and atherosclerosis are common disorders of
ageing and are among the main causes of morbidity and* Correspondence: sofia.ajeganova@ki.se
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stated.mortality in elderly [1,6]. Low bone mineral density
(BMD) has also been associated with severity of carotid
atherosclerosis and increased risk of echogenic calcified
atherosclerotic plaque [7-9].
Whether these two clinical conditions, also defined as
systemic disorders, are linked by common pathogenic
mechanisms or atherosclerosis per se, or whether osteo-
porosis is a cardiovascular risk factor remains unclear.
Risk factors for CVD, such as as hypertension, smoking,
dyslipidaemia, diabetes and oxidative stress have alsotral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Epidemiologic studies have consistently reported in-
verse associations between BMD and structural and
functional measures of atherosclerosis, seemingly inde-
pendent of age, sex and shared traditional cardiovascu-
lar risk factors [9,12,13].
Osteoporosis and atherosclerosis are common clinical
problems in inflammatory diseases, and inflammation
seems to play an important role in both conditions [14].
In systemic lupus erythematosus (SLE), cross-sectional
studies have revealed several disease-related risk factors
for low BMD, that is, long disease-duration, elevated
markers of inflammation, impaired renal function,
chronic organ damage and cumulative glucocorticoid
dose [15-19]. To date, underlying inflammatory im-
munological pathways for atherosclerosis and an in-
creased risk of CVD in SLE have been recognized.
Disease duration, disease activity, damage indices and
higher glucocorticoid dose have proved the most repro-
ducible non-traditional risk factors for progression of
atherosclerosis and CVD [20-23]. Hence, it certainly
seems plausible to think that there is also a relationship
between BMD and atherosclerosis in SLE, but the evi-
dence is lacking [24].
To our knowledge, no previous studies have evaluated
whether or not the association between BMD and ath-
erosclerosis differs between patients with SLE and indi-
viduals in the general population. Here, we examined
the association between bone mass and carotid measure-
ments in patients with SLE and age- and sex-matched
population-based controls. Then, we aimed to analyze if
disease-related factors, aside of traditional risk factors,
may explain the link between bone mineral health and
carotid atherosclerosis in SLE.
Methods
Patients
This study was based on participants included in the
SLE vascular impact cohort study (SLEVIC), details of
which have been published previously [25]. In brief, 114
patients with SLE, who fulfilled the 1982 revised criteria
of the American College of Rheumatology (ACR) for
SLE [26] and were younger than 70 years, and 122 aged-
and sex-matched controls (recruited randomly from the
same catchment area), were enrolled into the SLEVIC
cohort.
For the current analysis, participants of the derivation
cohort who underwent both dual-energy x-ray absorpti-
ometry (DXA) and carotid ultrasound examination were
identified. We then confirmed that each patient and his/
her control were similar in age and sex; these character-
istics are not of interest in themselves in the current
study, but are known to be estimations of the variables
we intended to study, that is, BMD and carotidmeasures. Thus, in this study we assessed a cohort of
111 patients and 111 controls who were matched indi-
vidually. The study was approved by the Regional Ethic
committee at Karolinska Institutet, Stockholm, and was
performed in accordance with the Declaration of
Helsinki. All study participants provided written in-
formed consent before entering the study.
Clinical assessment
Body mass index (BMI) was calculated as weight/height2
(kg/m2). Blood pressure was recorded in a seated pos-
ition with an automatic device by a trained nurse after
5 minutes rest. Hypertension was defined as systolic blood
pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg
and/or the use of antihypertensive medications and/or
previous diagnosis by a physician. Participants were
considered ever-smokers if they smoked at inclusion or
had smoked before. We recorded personal history of
CVD (coronary or peripheral arterial disease, ischaemic
stroke, transient ischaemic attack) and medication for
all participants using a questionnaire, and also medical
record review for the patients. Cumulative and average
dose of glucocorticoids (GC) and duration of GC ther-
apy were calculated. SLE activity was assessed with the
systemic lupus erythematosus diseases activity index
(SLEDAI) [27], and organ damage was measured using
the Systemic Lupus International Collaborating Clinics
(SLICC) damage index [28].
Laboratory assessment
Blood samples were collected after an overnight fast.
The biochemical analyses were determined by standard la-
boratory methods. Hypercholesterolaemia was determined
by fasting plasma cholesterol ≥5.0 mmol/l and/or the use
of lipid-lowering medications, and diabetes mellitus was
determined by fasting blood glucose ≥7.0 mmol/l and/or
the use of anti-diabetic medications. Hypercholesterol-
aemia and diabetes were also considered present if diag-
nosed by a physician.
Carotid ultrasound
As described in detail previously [25], the right and left
carotid arteries were examined with a duplex scanner
(Sequoia, Siemens Acuson, Mountain View, CA, USA)
using a -MHz linear array transducer. The far wall of the
common carotid artery (CCA), 0.5 to 1.0 cm proximal to
the beginning of the carotid bulb, was used for measure-
ments of the carotid intima-media thickness (cIMT).
The cIMT was defined as the distance between the lead-
ing edge of the lumen-intima echo and the leading edge
of the media-adventitia echo. The examinations were
digitally stored for subsequent analyses by a computer
system [29] with automated tracing of echo interfaces
and measurements of distances between the wall echoes
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fined by a simultaneous electrocardiographic recording.
The mean values of the cIMT within the 10-mm-long
section were calculated. The mean cIMT was calculated
as (right + left)/2. When a plaque was observed in the re-
gion of the CCA measurements, the cIMT was not
measured.
Carotid plaque was defined as a localized intima-
media thickening >1 mm and at least 100% increase in
thickness compared with adjacent wall segments. Plaque
was screened for in the common, internal and external
carotid arteries and described as the absence of plaque,
the presence of unilateral plaque, or bilateral plaque.
Plaque morphology in terms of echogenicity was
assessed in a modified version of the classification pro-
posed by Gray-Weale et al. [30] and graded from 1 to 4
ranging from low to strong echogenicity. Echolucency
was defined with the arterial lumen as reference and
echogenicity with the far wall adventitia as reference.
We considered grade-1 and/or grade-2 plaques to be
echolucent, and echogenic plaque was denoted as grade
3 and/or grade 4.
The difference between repeated measurements of cIMT
was 4.9% (coefficient of variation) using the automated ana-
lysis system. Repeated classification of plaque morphology
showed a correlation coefficient of 0.7 (P <0.05) between
the first and second classification (n = 50).
Bone mineral density
BMD was measured by DXA with a Lunar densitometer
(Lunar Corporation, Expert-XL software version 1.7,
Madison, USA, 1998). All BMD measurements were
expressed in absolute values in gram of bone mineral
per square centimetre (g/cm2) and as T-score, that is,
the number of SDs above or below the mean results of
healthy, young sex-matched adults (values obtained from
the Lunar combined European/US reference population).
Results are given for total body BMD, BMD at the hip
(total hip and femoral neck) and at the lumbar spine (ver-
tebrae L1 to L4; antero-posterior view). Low BMD was de-
fined as a T-score below −1.0, that is, osteopenia (T-score
−1.0 to −2.5) and osteoporosis (T-score below −2.5) ac-
cording to the World Health Organisation (WHO) criteria
for osteoporosis [31].
Statistical analysis
Continuous variables were summarized as mean (SD) or
median (IQR), as appropriate, and categorical variables as
frequencies (percentages). The chi-square test or Fisher's
exact test, or one-way analysis of variance (ANOVA) was
used for comparison as appropriate. Pearson correlation
was used to determine the bivariate association between
BMD and cIMT in the study groups separately. Taking
into account the possibility of non-linear continuousvariables, such as cIMT and BMD, we stratified these vari-
ables into tertiles.
Regression models were used to test independent asso-
ciation between BMD and carotid measurements in the
patients and controls (cIMT, presence or absence of ca-
rotid plaque as the dependent variables, and BMD and
study group as the independent variables), and to iden-
tify factors contributing to the association with carotid
atherosclerosis in the patients (traditional risk factors
and disease-related factors as the independent variables).
For the participants with plaque, the association between
BMD and plaque echogenicity was also tested by logistic
regression, where plaque echogenicity (graded in cat-
egories) was the dependent variable, and BMD and study
group were independent variables. To determine which
factors had significant influence on the relationship be-
tween BMD and carotid outcomes, we performed step-
wise multivariate analyses. The possible confounding
variables for the first-step models, such as hypertension,
hypercholesterolaemia, diabetes mellitus, history of
CVD, BMI and smoking, were all a priori prespecified
(as well-known risk factors for atherosclerosis) and
chosen for final models by Forward Wald selection pro-
cedure. The second-step model selected significant
disease-related factors by the same procedure. To the
final model variables identified in the first steps were en-
tered together. Variables of blood lipids were added to
the model individually. The groups were matched by sex
and age, thus, these covariates were not included in the
main analysis. Results of the logistic regression models
are presented as odds ratio (OR) with corresponding
95% CI, excluding zero which indicated significant dif-
ferences. The ability of BMD and disease-related covari-
ates to explain carotid atherosclerosis in the patient
group was assessed by receiver-operating characteristic
(ROC) curves. Two tailed significance tests at P-values
<0.05 were considered to be statistically significant. IBM
SPSS software version 22 (SPSS Inc., Chicago, IL, USA)
was used for the computations.
Results
Characteristics of patients and controls
Data on the whole original SLEVIC study population have
been presented previously [25]. The demographic and
clinical characteristics of patients and controls assembled
in the current analysis are shown in Table 1. Thus, signifi-
cant differences between the groups were found with re-
spect to presence of hypertension, history of previous
CVD, and to higher high-sensitivity C-reactive protein
(hsCRP) and ESR measures in the patients.
Regarding SLE-disease related features (described in
Table 2), the majority of the patients had had long-
standing disease at study inclusion, and had mild dis-
ease activity and low severity. A third of the patients
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levels (C3 <0.67 g/l, C4 <0.13 g/l and C1q <70 mg/l) were
found in 10%, 32% and 22% of the patients, respectively.
About 90% of the patients had at some time point been on
medication with GC, and 85% with antimalarial drugs.
Carotid IMT and plaque presence
Mean cIMT did not differ between the patients with
SLE and the controls. On the other hand, the frequency
of carotid plaque was higher in the patients than in the
controls, 45% versus 28%, P = 0.008. In both groups
echolucent plaques were more common than echogenic,
and both kinds of plaque were more common in the pa-
tients than in controls (Table 1).
Bone mineral density
The patients had significantly lower mean BMD mea-
surements at the total hip and femoral neck compared
with the controls; this was observed in the subgroup of
postmenopausal women (Table 3). However, there were
no differences between patients and controls in total and
lumbar spine BMD. Presence of osteoporosis and osteo-
penia, according to WHO criteria, in the lumbar spine
did not differ between the groups. On the other hand, a
higher proportion of low BMD in the hip was found in
patients compared with controls, 58% versus 45%.Table 1 Demographic, clinical and carotid ultrasound charact
and sex- and age-matched controls
SLE, n = 111
Age, years 48.6 (13.0)
Females, n % 99 (89.2%)
Postmenopausal, n (%) 48 (48.5%)
Body mass index, kg/m2 24.9 (4.4)
Ever smoking, n (%) 62 (55.9%)
Hypertension, n (%) 65 (58.6%)
Hypercholesterolaemia, n (%) 54 (48.6%)
Diabetes, n (%) 6 (5.4%)
History of cardiovascular disease, n (%) 15 (13.5%)
High-sensitivity C-reactive protein, mg/l 2.0 (0.8 to 4.8)
Erythrocyte sedimentation rate, mm/h 21.0 (12.3 to 3
Carotid measurements
Intima media thickness, mean, mm 0.62 (0.13)
Plaque presence, n (%)
No plaque 61 (55.0%)
Unilateral 20 (18.0%)
Bilateral 30 (27.0%)
Plaque echogenicity, n (%)
Echolucent (versus no plaque) 42 (37.8%)
Echogenic (versus no plaque) 13 (11.7%)
Values are number (percent), mean (SD) or median (IQR). P-values indicate betweenTwo-thirds of the patients were taking treatment for
osteoporosis, mostly calcium supplements and vitamin D
(64%), bisphosphonates (13%), and also hormone replace-
ment therapy (2%). Only about one tenth of controls were
prescribed medication for osteoporosis (Table 3).
Relation of BMD with carotid IMT measurements
When stratification of data according to normal BMD and
low BMD was done, we found no difference in age, sex or
BMI between the study groups, with age of about 42 years
in individuals with normal BMD (88% women) and 52 years
in those with low BMD values (97% women), and BMI of
about 25 kg/m2 in all. BMD was negatively associated with
cIMT measurements in both patients and controls, as dis-
played in Figure 1A-B. No statistically significant difference
between the groups was observed for this association.
Both patients and controls had higher cIMT if they
had low BMD, that is, mean cIMT (mm) 0.64 (0.13) in
the patients with low BMD, versus 0.57 (0.12) with nor-
mal BMD, P = 0.008; and corresponding means cIMT
(mm) 0.65 (0.13) versus 0.58 (0.10), P = 0.003 in the con-
trols. At low BMD (79 patients and 66 controls), the pa-
tients with any carotid plaque had higher cIMT than at
normal BMD, respective means cIMT (mm) 0.72 (0.11)
and 0.61 (0.15), P = 0.010, whereas such a difference was
not found in the controls.eristics of patients with systemic lupus erythematosus
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Table 2 Clinical features of the 111 systemic lupus
erythematosus (SLE) patients
Clinical variables Value
Duration SLE since diagnosis, years 9.0 (5.0 to 17.0) (range 0 to 40)
Systolic blood pressure, mmHg 127.7 (20.1)
Diastolic blood pressure, mmHg 78.7 (12.1)
A history of lupus nephritis, n (%) 38 (34.2%)
SLEDAI 2.0 (0 to 5.25) (range 0 to 27)
SLICC index 1 (0 to 3) (range 0 to 8)
Complement C3, g/l 0.93 (0.22)
Complement C4, g/l 0.17 (0.12 to 0.23)
Complement C1q, mg/l 88.6 (28.1)
Treatment variables













Ever use of glucocorticoids, n (%) 99 (89.2%)
Total duration of glucocorticoid
use, months
54 (14 to 113)
Total glucocorticoid cumulative dose, g 11.4 (3.5 to 24.5)
Average glucocorticoid dose, mg/day 4.3 (3.4)
Last year glucocorticoid
cumulative dose, g
1.4 (0 to 2,3)
Last year glucocorticoid
average dose, mg/day
3.8 (0 to 6.3)
Values are number (percent), mean (SD) or median (IQR) when not indicated
otherwise. SLEDAI, SLE disease activity index; SLICC, Systemic Lupus
International Collaborating Clinics.
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cent plaques were found at numerically lower cIMT
values in the patients than in the controls, respective
means cIMT (mm) 0.65 (0.16) versus 0.73 (0.17). Simi-
larly the cIMT values were lower in patients with echo-
genic carotid plaque than in the controls with that type
of plaque at normal BMD, means cIMT 0.67 (0.04) ver-
sus 1.08 (0).
Relation between BMD and occurrence and echogenicity
of carotid plaques
In both study groups, carotid plaques were more preva-
lent at lower BMD values (Figure 2). The group differ-
ence in the relationship between BMD measurements
and occurrence of carotid plaques derived from logisticregression is shown in Table 4. The results display a sys-
tematic pattern for more than doubled OR of detection
with carotid plaque in the patients than in the controls
in relation to all BMD measurements. In multivariate
analysis adjusted for hypertension, hypercholesterol-
aemia and history of CVD, the point estimates were
similar, but weaker association was indicated. For post-
menopausal women, however, approximately 2.5-times
increased OR were observed for carotid plaque across all
BMD measurements in the patients compared with the
controls. The results hardly changed when CRP, ESR
and use of treatment for osteoporosis were included in
the regression models.
Within normal BMD, but not within low BMD mea-
surements, there was a tendency towards echolucent ca-
rotid plaques to be detected more often in the patients
with SLE than in the controls, 34% versus 16%, P =
0.067. Prevalence of echogenic plaque did not differ be-
tween the study groups at normal and low BMD values.
For bone mass in total body and femoral neck, low
BMD and low T-scores significantly increased the OR
for presence of echolucent plaque versus no plaque in
the patients compared with the controls. Thus, for the
same total BMD at the hip, the adjusted OR (95% CI)
was 2.19 (1.05, 4.55), P = 0.036. The point estimates
hardly differed when the analysis was performed for total
body BMD, low total body BMD and lumbar spine BMD
values, though they did not reach statistical significance
with adjustments (P-values >0.05 and <0.06). In further
analysis for presence of echogenic plaque, approximately
4-fold increased ORs were observed for the patients
compared with the controls across all BMD measures,
thus, ORs (95% CI) were estimated as 3.77 (1.21, 11.71),
P = 0.022 at the same BMD body total. The results also
reflected a higher prevalence of echogenic plaque in the
patients than in the controls after adjustment for age,
sex, hypertension and hypercholesterolaemia, OR (95%
CI) 4.73 (1.21, 18.54), P = 0.026, but the estimated group
difference was smaller when controlled for history of
CVD, 2.39 (0.70, 8.14), P = 0.16.
Factors influencing association between BMD and carotid
measurements in patients with SLE
In search of pathomechanisms underlying the associ-
ation between low BMD and carotid atherosclerosis in
patients with SLE, we analysed the effect of potential
risk factors for this association, as presented in Table 5.
The following factors were found to have a significant
effect on detecting with higher cIMT and carotid plaque:
age, BMI, ever smoking, systolic blood pressure and a
low level of complement C4. The OR of higher cIMT
also increased relative to triglycerides and low levels of
complement C3 and C4, whereas the OR decreased rela-
tive to ever use of antimalarial drugs. On the other hand,
Table 3 Bone mineral density (BMD) in all patients with systemic lupus erythematosus (SLE) and sex- and age-matched
controls (*subanalysis of postmenopausal women only)
SLE, n = 111 Controls, n = 111 P-value
BMD, mg/cm2
Total body 1.119 (0.127) 1.130 (0.137) 0.563
Postmenopausal women* 1.056 (0.106) 1.064 (0.017) 0.724
Lumbar spine, vertebrae L1 to L4 1.134 (0.120) 1.153 (0.177) 0.456
Postmenopausal women* 1.058 (0.221) 1.075 (0.180) 0.668
Total hip 0.959 (0.151) 0.998 (0.139) 0.046
Postmenopausal women* 0.903 (0.126) 0.949 (0.138) 0.087
Femoral neck 0.909 (0.142) 0.958 (0.162) 0.017
Postmenopausal women* 0.846 (0.110) 0.893 (0.128) 0.048
T-score:
Total body 0.27 (1.20) 0.35 (1.23) 0.620
Postmenopausal women* −0.23 (1.04) −0.16 (1.22) 0.754
Lumbar spine, vertebrae L1 to L4 −0.45 (1.38) −0.38 (1.41) 0.683
Postmenopausal women* −0.96 (1.46) −0.97 (1.46) 0.974
Total hip −0.42 (1.24) −0.10 (1.09) 0.045
Postmenopausal women* −0.82 (1.07) −0.43 (1.15) 0.084
Femoral neck −0.66 (1.18) −0.32 (1.07) 0.026
Post-menopausal women* −1.12 (0.92) −0.73 (1.06) 0.054
BMD groups
Normal total body BMD 32 (28.8%) 45 (40.5%) 0.067
Postmenopausal women* 6 (12.5%) 11 (21.2%) 0.250
Low BMD, lumbar spine 60 (54.1%) 52 (46.8%) 0.283
Postmenopausal women* 33 (68.8%) 36 (69.2%) 0.959
Low BMD, total hip 64 (57.7%) 50 (45%) 0.060
Postmenopausal women* 35 (72.9%) 33 (63.5%) 0.311
Low BMD, femoral neck 69 (62.2%) 58 (52.3%) 0.136
Postmenopausal women* 38 (79.2%) 37 (73.1%) 0.476
Low BMD, at least one region 79 (71.2%) 66 (59.5%) 0.067
Postmenopausal women* 42 (87.5%) 41 (78.8%) 0.250
Treatments for osteoporosis, n (%):
Calcium supplement and/or vitamin D 71 (64.0%) 7 (6.3%) <0.001
Postmenopausal women* 34 (70.8%) 6 (11.5%) <0.001
Bisphosphonates 14 (12.6%) 4 (3.6%) 0.014
Postmenopausal women* 10 (20.8%) 4 (7.7%) 0.058
Hormone replacement therapy 2 (1.8%) 3 (2.7%) 1.0
Postmenopausal women* 2 (4.2%) 3 (5.8%) 1.0
Values are number (percentage and mean (SD)). P-values indicate between-group differences. Low BMD is defined as a T-score < −1.0 SD.
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blood lipids, diabetes mellitus, history of CVD, glomeru-
lar filtration rate (GFR) <60 ml/min/1.73 m2, history of
nephritis and SLICC.
In multivariate analysis, independent contributors to the
relationship between total body BMD and the upper cIMT
tertile were age and low C4 level, respective ORs (95% CI)2.32 (1.73, 2.95) per 10-year increase in age, P = <0.001,
and 3.21 (1.03, 10.01), P = 0.044. Then, age, history of
CVD, blood lipids and low C4 were independent con-
tributors to the relationship between BMD and bilateral
plaque. The effect of blood lipids, controlled for other
factors as above, yielded OR of 2.34 (1.21, 4.49), P =
0.011 for low-density lipoprotein (LDL) cholesterol,
Figure 1 Scatter plot of the relationship between total body bone mineral density (BMD) (A) and T-score (B), lowest at any region, and
carotid intima-media thickness (IMT) measurements in 111 patients with systemic lupus erythematosus (SLE) and 111 sex- and
age-matched controls. (A) The Pearson correlation coefficient was −0.26, P = 0.006 for the patients, and −0.27, P = 0.005 for the controls.
(B) The respective coefficients were −0.33, P = <0.001, and −0.24, P = 0.012.
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density lipoprotein (HDL) cholesterol, 4.34 (1.90, 9.89),
P = <0.001 for LDL/HDL, and 3.14 (1.20, 8.21), P =
0.020 for triglycerides, but the influence of total choles-
terol on this relationship was not statistically significant,
OR of 1.43 (0.91, 2.25), P = 0.124.Figure 2 Distribution of carotid plaque in relation to mean
total body bone mineral density (BMD) by tertiles in patients
with systemic lupus erythematosus (SLE) and sex- and age-
matched controls. BMD tertiles: 1 <1.067, 3 >1.183 mg/cm2.The receiver operating characteristic (ROC) curve ana-
lysis demonstrated that total body BMD explained 65%
(95% CI, 54, 75%, P = 0.010) of the variance in cIMT
measurements and presence of bilateral carotid plaque.
The best-fit multivariate model showed that age (OR
1.77, 95% CI 1.17, 2.41, P = 0.012), history of CVD (OR
9.15, 95% CI 1.85, 45.40, P = 0.007), LDL/HDL (OR 4.34,
95% CI 1.90, 9.89, P = <0.001), and low C4 (OR 4.84,
95% CI 1.03, 22.66, P = 0.046) were the optimal compo-
nents that accounted for the association between total
BMD and bilateral carotid plaque. The final models ex-
plained about 85% (95% CI 77, 96%, P = <0.001) of the
studied variance in carotid measures and had excellent
goodness-of-fit as described in the ROC curves, but the
performance of the models improved only modestly with
the addition of low C4 to the known traditional risk fac-
tors (Figure 3, A-B).
As a difference was observed between patients and
controls in the burden of carotid atherosclerosis at (sub)
normal BMD values, we next analysed whether disease
factors had a stronger impact on the studied association
within (sub)normal BMD ranges. The importance of low
C4 was found to be enhanced within the second and
third tertiles of total BMD (Figure 3, C-D) and particu-
larly pronounced for the association with bilateral ca-
rotid plaque. Other disease-specific variables did not
contribute independently to the relationship with carotid
measures within (sub)normal ranges of total BMD. The
Table 4 Odds ratio for carotid plaque in relation to bone mineral density (BMD) in systemic lupus erythematosus (SLE)
patients compared with matched controls





Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
BMD
Total body 2.11 (1.20, 3.72) 0.010 1.77 (0.96, 3.24) 0.066 2.62 (1.10, 6.24) 0.030
Lumbar spine, vertebrae L1 to L4 2.08 (1.18, 3.66) 0.011 1.75 (0.96, 3.21) 0.070 2.59 (1.08, 6.19) 0.032
Total hip 2.00 (1.14, 3.52) 0.016 1.74 (0.95, 3.18) 0.074 2.71 (1.13, 6.52) 0.026
Femoral neck 2.06 (1.17, 3.63) 0.013 1.76 (0.96, 3.22) 0.067 2.72 (1.14, 6.46) 0.024
T-score
Total body 2.12 (1.20, 3.74) 0.010 1.78 (0.97, 3.26) 0.064 2.63 (1.10, 6.26) 0.029
Lumbar spine, vertebrae L1 to L4 2.11 (1.20, 3.72) 0.009 1.78 (0.97, 3.26) 0.062 2.66 (1.12, 6.33) 0.027
Total hip 1.98 (1.13, 3.49) 0.018 1.72 (0.94, 3.15) 0.079 2.69 (1.12, 6.46) 0.027
Femoral neck 2.02 (1.14, 3.56) 0.016 1.74 (0.95, 3.19) 0.073 2.73 (1.15, 6.51) 0.023
WHO osteoporosis
Low BMD, lumbar spine 2.17 (1.23, 3.82) 0.008 1.73 (0.94, 3.19) 0.080 2.63 (1.09, 6.32) 0.031
Low BMD, total hip 1.98 (1.12, 3.49) 0.018 1.70 (0.93, 3.12) 0.085 2.75 (1.15, 6.58) 0.023
Low BMD, femoral neck 2.00 (1.13, 3.54) 0.017 1.72 (0.94, 3.16) 0.079 2.74 (1.15, 6.55) 0.024
Low BMD, at least one region 2.08 (1.19, 3.64) 0.010 1.78 (0.97, 3.24) 0.062 2.71 (1.14, 6.46) 0.024
Multivariate models were adjusted for hypertension, hypercholesterolaemia and history of cardiovascular disease. *Analysis of postmenopausal women only.
Low BMD is defined as a T-score < −1.0 SD. WHO, World Health Organisation.
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ments (data not shown).
Discussion
The study is the first to demonstrate an association be-
tween BMD and carotid measurements in patients with
SLE and age- sex-matched individuals from the general
population. Patients with SLE had a higher burden of ca-
rotid atherosclerosis than controls, expressed as higher
cIMT if they had carotid plaque and found to have low
BMD, as well as increased OR for carotid plaque in rela-
tion to all BMD measurements, particularly in postmeno-
pausal women. For BMD measures at the hip, we
observed an approximately two-fold increase in the OR
for the presence of echolucent carotid plaque, and for
BMD measures at any sites, more than a four-fold increase
in the OR for echogenic plaque in patients compared with
controls. Independent contributors to the association be-
tween BMD and higher cIMT values in the patients were
age and a low C4 level, and for the relationship between
BMD and bilateral carotid plaque they were age, history of
CVD, blood lipids (LDL and HDL cholesterol, LDL/HDL
ratio, triglycerides) and low C4. Total BMD, traditional
cardiovascular risk factors and hypocomplementemia C4
together explained about 85 to 90% of the variance in ca-
rotid IMT measurements and presence of bilateral carotid
plaque. Low C4 seems to be an important disease factor
contributing to the relationship between bone status and
carotid atherosclerosis in patients with SLE.The present findings support inverse association be-
tween bone mass and carotid measures of atheroscler-
osis in patients with SLE, in contrast to a recent report
[24]. Variation in studied populations, prevalence and
definition of outcomes in cross-sectional studies could
likely lead to divergent results. Thus, prevalence of
osteopenia and osteoporosis in our patients were higher
than previously reported in cross-sectional studies inves-
tigating bone health in SLE, which could arise due to
differences in study populations. Mendoza-Pinto et al.
found low BMD in 45% of premenopausal SLE patients
(mean age 33 years) of mixed-race, with median disease
duration of 6 years and lower cumulative exposure to
glucocorticoids (mean 20 g) [18]. Lakshminarayanan
et al., and Almehed et al. reported low BMD in about
60% of patients who were comparable with our study
population in terms of demographic and patient charac-
teristics [16,17]. Participants in our study, who were
older, had overt atherosclerotic disease, frequent trad-
itional cardiovascular risk factors, and more frequent ca-
rotid plaque (45% of patients) than reported by others
(11 to 37% of patients) [24,32,33]. Thus, the burden of
both low BMD and (sub)clinical atherosclerosis were
higher in the present study, which could have influenced
the study estimates if patients had not been matched
with individuals from the general population.
A number of epidemiological studies have suggested an
association between impaired bone metabolism and vascu-
lar calcification [34,35]. So far this relationship remains
Table 5 Potential contributors for the relationship between total body bone mineral density (BMD) and carotid
measurements in systemic lupus erythematosus (SLE) patients
Variable Carotid intima-media thickness mean
upper tertile, odds ratio (95% CI)
P-value Bilateral plaque,
odds ratio (95% CI)
P-value
Traditional factors
Age, per 10-year increase 2.29 (1.73, 2.89) <0.001 1.68 (1.23, 2.14) 0.003
Female 1.86 (0.46, 7.64) 0.387 1.90 (0.41, 8.87) 0.412
Body mass index, per 1-kg/m2 increase 1.18 (1.06, 1.32) 0.002 1.10 (0.99, 1.23) 0.070
Ever smoking, versus never 3.11 (1.29, 7.48) 0.011 2.99 (1.13, 7.93) 0.027
Blood pressure systolic, per 10-mmHg increase 1.43 (1.18, 1.68) 0.001 1.24 (1.01, 1.47) 0.040
Blood pressure diastolic, per 10-mmHg increase 1.18 (0.83, 1.54) 0.312 0.96 (0.61, 1.33) 0.847
Cholesterol total 1.26 (0.88, 1.80) 0.205 1.52 (1.03, 2.23) 0.036
Low-density lipoprotein cholesterol 1.42 (0.89, 2.26) 0.137 2.29 (1.32, 3.99) 0.003
High-density lipoprotein cholesterol 0.61 (0.26, 1.43) 0.254 0.21 (0.07, 0.66) 0.007
Low-density/high-density lipoprotein cholesterol 1.40 (0.86, 2.27) 0.171 3.37 (1.77, 6.42) <0.001
Triglycerides 2.26 (1.12, 4.57) 0.023 3.14 (1.46, 6.73) 0.003
Diabetes mellitus - 0.999 6.56 (1.11, 38.65) 0.038
History of cardiovascular disease 1.49 (0.48, 4.63) 0.493 7.44 (2.20, 25.15) <0.001
Disease factors
High-sensitivity C-reactive protein, per 10 mg/l increase 1.30 (0.61, 2.04) 0.404 0.97 (0.90, 1.51) 0.475
Erythrocyte sedimentation rate, per 10 mm/h increase 1.02 (0.78, 1.27) 0.874 1.17 (0.91, 1.43) 0.206
Low C3 < 0.67 g/l 7.25 (0.86, 60.83) 0.068 1.85 (0.36, 9.41) 0.461
Low C4 < 0.13 g/l 3.04 (1.14, 8.08) 0.026 4.03 (1.25, 13.04) 0.020
Low C1q <70 mg/l 1.04 (0.36, 2.99) 0.941 0.98 (0.31, 3.12) 0.973
Glomerular filtration rate <60 ml/min/1.73 m2 1.50 (0.54, 4.12) 0.437 2.77 (1.04, 7.42) 0.042
Disease duration since diagnosis, years, per 10-year increase 1.08 (0.66, 1.52) 0.712 1.00 (0.96, 1.05) 0.869
History of lupus nephritis 1.02 (0.44, 2.39) 0.963 2.47 (1.01, 6.02) 0.047
SLE disease activity index 0.95 (0.87, 1.05) 0.319 0.99 (0.90, 1.09) 0.825
Systemic Lupus International Collaborating Clinics 1.11 (0.91, 1.34) 0.316 1.34 (1.08, 1.66) 0.007
Ever use of antimalarial drugs 0.30 (0.10, 0.92) 0.036 0.89 (0.27, 2.91) 0.850
Ever use of glucocorticoids 2.15 (0.53, 8.76) 0.287 1.25 (0.34, 4.63) 0.741
Total duration of glucocorticoid use, per 10-month increase 1.01 (0.96, 1.06) 0.663 1.00 (0.96, 1.06) 0.682
Total cumulative glucocorticoid dose, per 10-g increase 1.05 (0.83, 1.27) 0.688 1.12 (0.90, 1.35) 0.274
Average daily dose of glucocorticoid 1.03 (0.91, 1.16) 0.694 1.06 (0.93, 1.20) 0.420
Last year cumulative dose of glucocorticoid 0.89 (0.70, 1.13) 0.336 0.81 (0.61, 1.08) 0.148
Last year average daily dose of glucocorticoid 0.96 (0.88, 1.05) 0.336 0.93 (0.84, 1.03) 0.148
Values are OR with 95% CI analysed by multiple logistic regression. cIMT mean upper tertile >0.659 mm.
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underestimated. Presently, vascular calcification is regarded
as an active process, regulated by factors known to be in-
volved in the process of osteogenesis, such as bone
morphogenetic protein, osteopontin, the receptor acti-
vator of nuclear factor kappa B (RANK) ligand-RANK-
osteoprotogerin (OPG) pathway, matric Gla protein
and the Wnt signalling pathway [14]. Thus, coinci-
dence of vascular calcification with low bone activity
could be biologically linked. During the developmentof vascular calcification, the transition of vascular
smooth muscle cells towards an osteoblast-like pheno-
type and mineralization within these structures is pro-
moted by several players including those related to
mineral metabolism [10]. Still, an intriguing question
is whether the presence of vascular calcification im-
pacts bone metabolism, thus demonstrating true cross-
talk between these tissues. An additional important
question is whether or not progression of vascular cal-
cification can be prevented or restricted. Although data
Figure 3 Receiver operating characteristic (ROC) curves for association between total body bone mineral density (BMD) (A-B) the
middle and upper tertiles of total body BMD, ≥1.067 mg/cm2 (C-D) and the upper mean (>0.659 mm) carotid intima-media thickness
(cIMT) (A, C) and bilateral carotid plaque (B, D) in patients with systemic lupus erythematosus (SLE). The curves are based on multivariate
models with traditional risk factors alone (dashed lines) or together with (solid lines) a low level of complement C4 (<0.13 g/l). For total body
BMD in association with higher cIMT (A) areas under the ROC curves are 0.840 (95% CI 0.768, 0.912, P <0.001) and 0.858 (0.789, 0.927, p = <0.001)
in corresponding models; and in association with bilateral carotid plaque (B) areas are 0.869 (0.797, 0.940, P <0.001) and 0.886 (0.813, 0.958, P <0.001),
respectively. For association between the middle and upper tertiles of total body BMD and upper mean cIMT (C), areas under the ROC curves are
0.850 (0.777, 0.923, P <0.001) in analyses incorporating traditional risk factors, and 0.863 (0.786, 0.941, P <0.001) in models that also included low C4;
respective areas for association with bilateral carotid plaque (D) are 0.869 (0.792, 0.946, P <0.001) and 0.911 (0.848, 0.974, P <0.001).
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with calcium and vitamin D that may increase vascular
calcification and risk of CV events [36], bisphospho-
nates may act protectively against atherosclerosis [37].Oestrogen deficiency and premature menopause are
considered important risk factors for osteoporosis, and
also for atherosclerosis [38]. Recently, increased risk for
developing CVD was shown for women with rheumatoid
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pro-inflammatory cytokines and the RANK system have
been suggested as common pathogenic links modulated
by oestrogen. Here, in postmenopausal women we found
an independent significant association between BMD
and carotid plaque. Then, notably, among postmeno-
pausal women, we observed lower hip BMD values in
patients compared with controls. Bone microstructure
and metabolic activity differ at different sites and bone
loss in trabecular bone is considered more pronounced
than in mostly cortical bone. In SLE, however, marked
loss of cortical area as well as trabecular volume in the
femur even without GC treatment, and also a lower hip
BMD compared to controls, have been shown [40,41],
suggesting deleterious effect of disease per se on bone
metabolism. In middle-aged women with SLE, a higher
carotid plaque index has been also described in patients
in the lower tertiles of total hip BMD, but without a re-
lationship to the lumbar spine bone measures [42]. In
elderly women, low BMD in the hip seems to be a
marker of atherosclerosis [43]. Thus, the finding of
stronger association between low BMD in the hip and
echolucent carotid plaque in our study was not unlikely.
To the best of our knowledge, no previous study has
examined whether carotid plaque morphology, in terms
of echogenicity, relates to BMD in SLE. In the general
population, it has been reported that the prevalence of
echogenic plaque, having a higher content of calcified
material and fibrous tissue, was significantly related to
low BMD, but no association was found between BMD
and echolucent plaque, having a higher content of lipid,
necrotic debris and/or haemorrhage [44]. Here, we ob-
served a two-fold increased OR for echolucent plaque in
the patients than in the controls at the same hip BMD
values, and a four-fold increase for echogenic plaque with
adjustment for age, sex, hypertension and hypercholester-
olaemia. The estimated group difference for detection with
echogenic plaque was smaller when controlling for history
of CVD, but overt atherosclerotic disease is in the causal
pathway with carotid plaque, and to which degree adjust-
ments should be made when assessing the strength of as-
sociation between osteoporosis and carotid measurements
is unclear. Notably, the prevalence of echolucent carotid
plaque was numerically higher in the patients than in the
controls within normal BMD values, and echogenic pla-
ques were found at lower cIMT values in patients than in
the controls with that type of plaque within normal BMD.
Further, plaque of both types of echogenicity were de-
tected at numerically lower cIMT values in the patients
compared with the controls within normal BMD. In line
with our observation, Frerix et al. frequently found athero-
sclerotic plaque lesions in the absence of intima-media
thickening in both SLE and systemic sclerosis patients
[45]. Altogether, our results suggest that patients with SLEmay already have premature atherosclerosis within BMD
ranges of normal bone mass.
We observed that LDL cholesterol, LDL/HDL ratio
and triglycerides were among the factors independently
inversely related to the association between BMD and
carotid measurements in patients, whereas HDL choles-
terol showed a protective effect. Several studies in vitro
have previously suggested that abnormal lipid profile
may be the key factor responsible for the inverse associ-
ation between BMD and atherosclerosis, as lipids modu-
late bone remodeling and the atherosclerotic process in
opposite directions [46,47]. This suggestion however has
not been verified in human studies [48,49], and in a
study of elderly women none of the lipids contributed
independently to the variation in BMD [50]. The role of
lipids in regulation of bone mass in SLE is unclear. Tak-
ing into account the evidence linking inflammatory al-
tered lipid profile to premature atherosclerosis in SLE, it
is reasonable to hypothesize that lipids may be in the
pathogenic pathway and relate to bone loss too.
The deleterious effect of the SLE-disease per se on bone
metabolism is supported by clinical studies, which suggest
there is lower BMD in SLE patients even without prior
GC exposure, compared with healthy controls [51]. It is
also well-established that a high cumulative inflammatory
burden in SLE patients is associated with reduced BMD
and presence of atherosclerosis [19,23]. Our present study
further addressed this issue and the results of univariate
analysis suggest that the low level of complement C3 and
C4, low GFR, history of nephritis, damage-index SLICC,
and ever use of antimalarial drugs could be of importance
in the relationship between disease and bone health, and
arterial vessel health. Of these, hypocomplementaemia C4
was an independent factor for the relationship, particularly
within (sub)normal ranges of total BMD. It has been im-
plicated that many pathogenetic mechanisms behave para-
doxically in inflammatory condition, compared with
general population. Thus, substantial positive correlation
of higher complement factors C3 and C4 with cardiovas-
cular risk factors and risk of CVD have been reported in
population-based studies [52]. Whether complement func-
tion regulates bone turnover, for example, indirectly
through effects on the immune system, is unknown. In the
present study, multivariate analysis controlling for BMD,
age, sex, hypertension, hypercholesterolaemia, history of
CVD, lipids and low C4, together explained about 85%
of the variance in carotid measurements. Although the
performance of adjusted models improved only mod-
estly with addition of low C4, traditional and inflammatory
dependent risk factors together may more accurately de-
fine the processes that lead to the development of bone
loss and atherosclerosis.
The SLE patients in our study had mild disease activity
and low severity and were on long-term, low-dose GC
Ajeganova et al. Arthritis Research & Therapy  (2015) 17:84 Page 12 of 13therapy. Therefore one cannot infer a similar effect size
in other patient populations. Furthermore, the SLE pa-
tients were given supplements of calcium with vitamin
D and treated with bisphosphonates, which might have
played a role in minimizing the study estimates.
Conclusion
This study demonstrates associations between BMD
and carotid measures in patients with SLE and
population-based matched controls and suggests a
higher burden of carotid atherosclerosis at the same
bone mass in patients than in controls. Longitudinal
studies are needed to prove the pathophysiological rela-
tionship. The message for clinical practice is that diag-
nosis and treatment of bone loss in patients with SLE
should include consideration of cardiovascular risk as-
sessment to improve cardiovascular outcomes; con-
versely, detection of (sub)clinical atherosclerosis should
prompt consideration of densitometry to diagnose and
prevent complications of osteoporosis.
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